.jpg)
1 hour ago
3
Article content
VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company will present 4 abstracts at Digestive Disease Week (“DDW”) Annual meeting being held May 2-5, 2026 in Chicago, Illinois. Clinical data will be presented from the ongoing Phase 1b/2 RESOLVE trial of EP-104GI for the treatment of eosinophilic esophagitis (“EoE”).
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Article content
Oral Presentation:
Article content
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
Lecture Session: EoE: Advances in Management
Date: May 3, 2026
Time: 10:15-10:30 AM CDT
Title: Administration of escalating doses of EP-104GI leads to persistent improvements in histological features of eosinophilic esophagitis over 36 weeks in RESOLVE, a Phase 1b/2 dose escalation and optimization trial.
Presenter: Chris Ma, University of Calgary
Article content
Poster Presentations:
Article content
Poster Session: Eosinophilic Esophagitis: Treatment
Date: May 5, 2026
Time: 12:30 PM to 1:30 PM CDT
Article content
Title: Single administration of EP-104GI in RESOLVE, a Phase 1b/2 trial in eosinophilic esophagitis, improves endoscopic features of inflammation and fibrosis over 36 weeks.
Presenter: Nirmala Gonsalves, Northwestern University
Article content
Title: Durability of dysphagia improvements following single administration of EP-104GI in participants with eosinophilic esophagitis during dose escalation in the RESOLVE trial.
Presenter: Arjan Bredenoord, UMC Amsterdam
Article content
Title: Determination of dose and injection pattern of EP-104GI through dose escalation in RESOLVE: a Phase 1b/2, multicenter trial to evaluate safety, tolerability, pharmacokinetics and efficacy in adults with EoE.
Presenter: Evan Dellon, University of North Carolina
Article content
Article content
Materials will be available after the presentations on Eupraxia’s website at:
Article content
Article content
Investor event at DDW 2026
Article content
The Company will also be hosting a virtual investor event on Monday, May 4 at 7am CT / 8am ET at Digestive Disease Week (DDW). The event will feature key opinion leaders (KOLs) Evan S. Dellon, MD, MPH (University of North Carolina School of Medicine) and Jeffrey D. Mosko, MD, MSc, FRCPC (University of Toronto), who will discuss the definition, prevalence, and treatment of recurrent esophageal strictures.
Article content
Company management will also highlight the potential of its lead product candidate EP-104GI for the prevention of esophageal strictures. EP-104GI is a long-acting submucosal corticosteroid formulation to be injected within esophageal tissues, which has the potential to increase patient adherence by requiring fewer interventions while addressing local inflammation.
Article content
Article content
About Eupraxia Pharmaceuticals Inc.
English (US)